Rachel Eides News Today

ZUG, Switzerland and BOSTON, April 22, 2024 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an...

 —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 -- CRISPR Therapeutics , a biopharmaceutical...

(2024-02-13 | NDAQ:CRSP) CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Vertex and CRISPR Therapeutics have announced FDA approval for CASGEVY in treating sickle cell disease. Utilizing cutting edge CRISPR/Cas9 gene editing technology, a patient’s own genes are extracted, edited, and then reinserted to eliminate sickle cell in this new therapy.

– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. –– Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment –– Multiple authorized treatment centers activated –BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Ph...

-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70- -Expanding trials of CTX112 into...

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Nov 16, 2023--

-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 202...

Switzerland - CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the...

ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...